What Makes BioMarin (BMRN) so Attractive

Core Insights - BioMarin Pharmaceutical (NASDAQ:BMRN) is identified as one of the 17 biotechnology stocks with over 50% upside potential, with a projected median 1-year price target of $88.29, indicating more than 47% upside from its current level [1] - Analyst sentiment is moderately bullish, with 10 out of 15 analysts rating the stock as Buy and 5 as Hold, with no Sell ratings [1] - Piper Sandler's analyst Allison Bratzel reiterated an Overweight rating on BioMarin, reducing her price target from $122 to $84, which still suggests over 40% upside potential [2] Company Overview - BioMarin Pharmaceutical specializes in developing and commercializing targeted therapies for life-threatening medical conditions and rare genetic diseases, with key products including VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME [3] - The company operates in more than 70 countries and has several drugs currently in the development stage [3]